POSACONAZOLE Side Effects

7006475-6 | Abasia, Areflexia, Mucosal Inflammation, Muscular Weakness, Neurotoxicity, Organising Pneumonia, Peroneal Nerve Palsy, Thrombocytopenia
on Mar 09, 2007 Male patient from GREECE , 21 years of age, was diagnosed with febrile neutropenia, acute lymphocytic leukaemia and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: abasia, areflexia, mucosal inflammation, muscular weakness, neurotoxicity, organising pneumonia, peroneal nerve palsy, thrombocytopenia. Posaconazole dosage: 400 Mg;bid;po. During the same period patient was treated with VINCRISTINE (2 Mg;qw) (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ).

7006473-2 | Abdominal Pain, Acute Lymphocytic Leukaemia, Brain Oedema, Constipation, Convulsion, Encephalopathy, Fusarium Infection, Hypokalaemia
Patient was taking Posaconazole (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), acute lymphocytic leukaemia, brain oedema, constipation (What is constipation?), convulsion, encephalopathy, fusarium infection, hypokalaemia on Jun 02, 2009 from FRANCE Additional patient health information: Female patient , child 9 years of age, was diagnosed with antifungal prophylaxis and. Posaconazole dosage: 50 Mg;tid;po. During the same period patient was treated with VINCRISTINE (1.8 Mg;once;iv, 1.8 Mg; Once Iv) (View Vincristine Review and Vincristine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6973595-1 | Renal Failure
Adverse event was reported on Aug 31, 2010 by a Male patient taking Posaconazole (View Usage) (Dosage: 200 Mg; Tid; Po) was diagnosed with infection prophylaxis and. Location: LITHUANIA , child 12 years of age, weighting 94.80 lb, After Posaconazole was administered, patient had the following side effects: renal failure. During the same period patient was treated with URSOSAN (View Ursosan Review and Ursosan Label ), HEPATIL (View Hepatil Review and Hepatil Label ), METRONIDASOLI (View Metronidasoli Review and Metronidasoli Label ), LANZOSTAD (View Lanzostad Review and Lanzostad Label ), SINGULAIR (View Singulair Review and Singulair Label ), RANIDITINI (View Raniditini Review and Raniditini Label ), LEXATONILI (View Lexatonili Review and Lexatonili Label ), SOL. MITILPREDNIZALONI (View Sol. Mitilprednizaloni Review and Sol. Mitilprednizaloni Label ).

6959557-9 | Renal Failure, Therapeutic Agent Toxicity, Urine Output Decreased
on Aug 11, 2010 Female patient from LITHUANIA , child 12 years of age, was diagnosed with antifungal prophylaxis and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure, therapeutic agent toxicity, urine output decreased. Posaconazole dosage: 200 Mg;tid;po. During the same period patient was treated with URSOSAN (View Ursosan Review and Ursosan Label ), HEPATIL (View Hepatil Review and Hepatil Label ), METRONIDASOLI (View Metronidasoli Review and Metronidasoli Label ), LANZOSTAD (View Lanzostad Review and Lanzostad Label ), SINGULAIR (View Singulair Review and Singulair Label ), RANIDITINI (View Raniditini Review and Raniditini Label ), LEXATONILI (View Lexatonili Review and Lexatonili Label ), SOL. MITILPREDNIZALONI (View Sol. Mitilprednizaloni Review and Sol. Mitilprednizaloni Label ).


6931246-6 | Condition Aggravated, Dyspnoea, Psoriasis
on Aug 09, 2010 Female patient from UNITED KINGDOM , 71 years of age, weighting 135.6 lb, was diagnosed with bronchopulmonary aspergillosis and was treated with Posaconazole (View Usage). Patient had the following side effects: condition aggravated, dyspnoea, psoriasis. Posaconazole dosage: 400 Mg;bid;po. During the same period patient was treated with WARFARIN SODIUM (View Warfarin Sodium Review and Warfarin Sodium Label ).

6861361-7 | Hepatic Enzyme Increased, Hypocalcaemia, Hyponatraemia, Liver Function Test Abnormal
Patient was taking Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: hepatic enzyme increased, hypocalcaemia, hyponatraemia, liver function test abnormal on Jul 12, 2010 from AUSTRALIA Additional patient health information: Male patient , 99 years of age, . Posaconazole dosage: . During the same period patient was treated with CASPOFUNGIN ACETATE (View Caspofungin Acetate Review and Caspofungin Acetate Label ), ITRACONAZOLE (Po) (View Itraconazole Review and Itraconazole Label ), VORICONAZOLE (400 Mg;qd;po) (View Voriconazole Review and Voriconazole Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ). Patient was hospitalized.

6688863-0 | Diarrhoea, Enterobacter Infection, Gastrointestinal Toxicity, Hepatotoxicity, Hyperbilirubinaemia, Septic Shock
Adverse event was reported on Feb 24, 2010 by a Female patient taking Posaconazole (View Usage) (Dosage: 600 Mg; ; Po) was diagnosed with antifungal prophylaxis, acute promyelocytic leukaemia and. Location: SPAIN , 33 years of age, Patient experienced the following unwanted or unexpected effects: diarrhoea, enterobacter infection, gastrointestinal toxicity, hepatotoxicity, hyperbilirubinaemia, septic shock. During the same period patient was treated with ATRA (ALL TRANS RETINOIC ACID) (TRETINOIN) (80 Mg; ; Po) (View Atra (all Trans Retinoic Acid) (tretinoin) Review and Atra (all Trans Retinoic Acid) (tretinoin) Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

6639201-0 | Bronchopulmonary Aspergillosis, Central Nervous System Lymphoma, Cerebral Aspergillosis, Cholelithiasis, Graft Dysfunction, Myopathy, Neurological Decompensation, Pleural Effusion
on Mar 08, 2010 Male patient from SPAIN , 63 years of age, was diagnosed with prophylaxis against graft versus host disease and was treated with Posaconazole (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis, central nervous system lymphoma, cerebral aspergillosis, cholelithiasis, graft dysfunction, myopathy, neurological decompensation, pleural effusion. Posaconazole dosage: . During the same period patient was treated with LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), LOW MOLECULAR WEIGHT HEPARIN (View Low Molecular Weight Heparin Review and Low Molecular Weight Heparin Label ), .. (View .. Review and .. Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6618065-5 | Acute Graft Versus Host Disease In Intestine, Brain Herniation, Brain Oedema, Bronchopulmonary Aspergillosis, Central Nervous System Lymphoma, Cerebral Aspergillosis, Cholelithiasis, Culture Urine Positive
on Feb 23, 2010 Male patient from SPAIN , 63 years of age, was diagnosed with prophylaxis and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: acute graft versus host disease in intestine, brain herniation, brain oedema, bronchopulmonary aspergillosis, central nervous system lymphoma, cerebral aspergillosis, cholelithiasis, culture urine positive. Posaconazole dosage: . During the same period patient was treated with LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), LOW MOLECULAR WEIGHT (View Low Molecular Weight Review and Low Molecular Weight Label ), HEPARIN (View Heparin Review and Heparin Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6616883-0 | Condition Aggravated, Liver Abscess
Patient was taking Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: condition aggravated, liver abscess on Feb 23, 2010 from GERMANY Additional patient health information: Male patient , 21 years of age, was diagnosed with lung infection, antifungal prophylaxis and. Posaconazole dosage: 200 Mg;qid. During the same period patient was treated with RIFAMPICIN (View Rifampicin Review and Rifampicin Label ), MICAFUNGIN (MICAFUNGIN) (View Micafungin (micafungin) Review and Micafungin (micafungin) Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), LINEZOLID (View Linezolid Review and Linezolid Label ). Patient was hospitalized.

6615757-9 | Abdominal Pain, Blood Bilirubin Increased, Diarrhoea, Enterobacter Infection, Septic Shock
Adverse event was reported on Feb 19, 2010 by a Female patient taking Posaconazole (View Usage) (Dosage: ) was diagnosed with antifungal prophylaxis, leukaemia and. Location: SPAIN , 33 years of age, Patient had the following side effects: abdominal pain (What is abdominal pain?), blood bilirubin increased, diarrhoea, enterobacter infection, septic shock. During the same period patient was treated with ATRACURIUM BESYLATE (View Atracurium Besylate Review and Atracurium Besylate Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ).

6615556-8 | Abdominal Pain, Diarrhoea, Enterobacter Infection, Gastrointestinal Toxicity, Hepatotoxicity, Hyperbilirubinaemia, Multi-organ Failure, Septic Shock
on Feb 24, 2010 Female patient from SPAIN , 33 years of age, was diagnosed with antifungal prophylaxis, acute promyelocytic leukaemia and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), diarrhoea, enterobacter infection, gastrointestinal toxicity, hepatotoxicity, hyperbilirubinaemia, multi-organ failure, septic shock. Posaconazole dosage: 600 Mg;po. During the same period patient was treated with ATRACURIUM BESYLATE (80 Mg; Po) (View Atracurium Besylate Review and Atracurium Besylate Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MEROPENEM (View Meropenem Review and Meropenem Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

6597717-X | Ephelides, Erythema, Photosensitivity Reaction, Refusal Of Treatment By Patient, Skin Disorder, Squamous Cell Carcinoma, Sunburn, Treatment Noncompliance
on Feb 03, 2010 Male patient from AUSTRALIA , 25 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: ephelides, erythema, photosensitivity reaction, refusal of treatment by patient, skin disorder, squamous cell carcinoma, sunburn, treatment noncompliance. Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6593809-X | Ephelides, Fungal Infection, Photosensitivity Reaction, Squamous Cell Carcinoma, Sunburn
Patient was taking Posaconazole (View Usage). Patient had the following side effects: ephelides, fungal infection (What is fungal infection?), photosensitivity reaction, squamous cell carcinoma, sunburn on Feb 03, 2010 from AUSTRALIA Additional patient health information: Male patient , 25 years of age, was diagnosed with fungal infection (What is fungal infection?) and. Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6549077-8 | Pulmonary Haemorrhage, Thrombocytopenia, Treatment Failure, Zygomycosis
Adverse event was reported on Jan 12, 2010 by a Male patient taking Posaconazole (View Usage) (Dosage: 200 Mg; Tid;, 400 Mg; Bid;) was diagnosed with antifungal prophylaxis and. Location: GERMANY , 60 years of age, After Posaconazole was administered, patient had the following side effects: pulmonary haemorrhage, thrombocytopenia, treatment failure, zygomycosis.

6523139-3 | C-reactive Protein Increased, Condition Aggravated, Cough, Fatigue, Microsporum Infection, Pancytopenia, Pulmonary Haemorrhage, Pulmonary Necrosis, Treatment Failure
on Dec 15, 2009 Male patient from GERMANY , 60 years of age, was diagnosed with antifungal prophylaxis and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: c-reactive protein increased, condition aggravated, cough, fatigue, microsporum infection, pancytopenia, pulmonary haemorrhage, pulmonary necrosis, treatment failure. Posaconazole dosage: 200 Mg, Tid, 400, Mg, Bid,.

6447392-X | Encephalitis, Encephalopathy, Liver Disorder
on Nov 11, 2009 Female patient from UNITED KINGDOM , 42 years of age, was treated with Posaconazole (View Usage). Patient had the following side effects: encephalitis (What is encephalitis?), encephalopathy, liver disorder. Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), ALENDRONIC ACID (View Alendronic Acid Review and Alendronic Acid Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ).

6447387-6 | Encephalitis, Encephalopathy, Hepatic Function Abnormal
Patient was taking Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: encephalitis (What is encephalitis?), encephalopathy, hepatic function abnormal on Nov 11, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 42 years of age, . Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), ALENDRONIC ACID (View Alendronic Acid Review and Alendronic Acid Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), CO TRIMOXAZOLE (View Co-trimoxazole Review and Co-trimoxazole Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), HYDROCORTIZONE (View Hydrocortizone Review and Hydrocortizone Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), SERTRALINE HCL (View Sertraline Hcl Review and Sertraline Hcl Label ).

6411212-X | Acute Pulmonary Oedema, Blood Ph Decreased, Bronchopulmonary Aspergillosis, Heart Rate Increased, Pco2 Decreased, Pulmonary Hilar Enlargement, Refusal Of Treatment By Patient, Respiratory Failure
Adverse event was reported on Apr 20, 2009 by a Female patient taking Posaconazole (View Usage) (Dosage: 10 Ml; Bid; Po) was diagnosed with fungal infection (What is fungal infection?) and. Location: CHINA , 29 years of age, weighting 138.9 lb, Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, blood ph decreased, bronchopulmonary aspergillosis, heart rate increased, pco2 decreased, pulmonary hilar enlargement, refusal of treatment by patient, respiratory failure. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CEFOPEERAZONE (View Cefopeerazone Review and Cefopeerazone Label ), SULBACTAM (View Sulbactam Review and Sulbactam Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ).

6392190-9 | Incision Site Abscess, Lymphadenopathy, Metastasis, Recurrent Cancer, Skin Exfoliation, Squamous Cell Carcinoma, Wound Infection
on Sep 28, 2009 Male patient from UNITED STATES , 50 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Posaconazole (View Usage). Patient had the following side effects: incision site abscess, lymphadenopathy, metastasis, recurrent cancer, skin exfoliation, squamous cell carcinoma, wound infection. Posaconazole dosage: 400 Mg; Bid; Po. During the same period patient was treated with KEPPRA (View Keppra Review and Keppra Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), FLUCYTOSINE (View Flucytosine Review and Flucytosine Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6381060-8 | Encephalitis, Encephalopathy, Liver Disorder
on Sep 21, 2009 Female patient from UNITED KINGDOM , 42 years of age, was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: encephalitis (What is encephalitis?), encephalopathy, liver disorder. Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), ALENDRONIC ACID (CON.) (View Alendronic Acid (con.) Review and Alendronic Acid (con.) Label ), AZITHROMYCIN (CON.) (View Azithromycin (con.) Review and Azithromycin (con.) Label ), CO TRIMOXAZOLE (CON.) (View Co-trimoxazole (con.) Review and Co-trimoxazole (con.) Label ), CYCLIZINE (CON.) (View Cyclizine (con.) Review and Cyclizine (con.) Label ), HYDROCORTISONE (CON.) (View Hydrocortisone (con.) Review and Hydrocortisone (con.) Label ), OMEPRAZOLE (CON.) (View Omeprazole (con.) Review and Omeprazole (con.) Label ), SERTALINE (CON.) (View Sertaline (con.) Review and Sertaline (con.) Label ).

6377260-3 | Thrombocytopenia
Patient was taking Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: thrombocytopenia on Sep 24, 2009 from UNITED STATES Additional patient health information: Male patient , 67 years of age, weighting 245.0 lb, was diagnosed with upper respiratory tract infection and. Posaconazole dosage: 5 Ml Tid Po.

6339963-6 | Encephalopathy
Adverse event was reported on Aug 25, 2009 by a Male patient taking Posaconazole (View Usage) (Dosage: ) was diagnosed with aspergilloma, epilepsy (What is epilepsy?) and. Location: AUSTRALIA , 48 years of age, Patient had the following side effects: encephalopathy. During the same period patient was treated with TOPIRAMATE (View Topiramate Review and Topiramate Label ), VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ). Patient was hospitalized.

6335143-9 | Catatonia, Decreased Appetite, Encephalopathy, Hypophagia, Sepsis, Somnolence
on Aug 18, 2009 Male patient from AUSTRALIA , 48 years of age, was diagnosed with aspergilloma, epilepsy (What is epilepsy?) and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: catatonia, decreased appetite, encephalopathy, hypophagia, sepsis (What is sepsis?), somnolence. Posaconazole dosage: 200 Mg; Qid; Unk. During the same period patient was treated with TOPIRAMATE (100 Mg; Bid; Unk) (View Topiramate Review and Topiramate Label ), VALPROIC ACID (700 Mg; Bid; Unk) (View Valproic Acid Review and Valproic Acid Label ). Patient was hospitalized.

6305533-9 | Encephalitis, Encephalopathy, Hepatic Function Abnormal
on Jul 29, 2009 Female patient from UNITED KINGDOM , 42 years of age, was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: encephalitis (What is encephalitis?), encephalopathy, hepatic function abnormal. Posaconazole dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), ALENDRONIC ACID (View Alendronic Acid Review and Alendronic Acid Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), COTRIM (View Cotrim Review and Cotrim Label ), CYCLIZINE (View Cyclizine Review and Cyclizine Label ), HYDROCORTIZONE (View Hydrocortizone Review and Hydrocortizone Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

6278480-9 | Acute Myeloid Leukaemia, Altered State Of Consciousness, Cardiomegaly, Cardiomyopathy, Convulsion, Hypotension, Multi-organ Failure
Patient was taking Posaconazole (View Usage). Patient had the following side effects: acute myeloid leukaemia, altered state of consciousness, cardiomegaly, cardiomyopathy (What is cardiomyopathy?), convulsion, hypotension, multi-organ failure on Jul 16, 2009 from TAIWAN, PROVINCE OF CHINA Additional patient health information: Female patient , 18 years of age, weighting 92.59 lb, was diagnosed with fungal infection (What is fungal infection?), acute myeloid leukaemia and. Posaconazole dosage: 10 Ml;bid;po. During the same period patient was treated with AMBISOME (5 Mg;qd;indrp) (View Ambisome Review and Ambisome Label ), CYTARABINE (1000 Mg;qd;indrp) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (8 Mg;once;indrp) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), CASPOFUNGIN (View Caspofungin Review and Caspofungin Label ).

6252179-7 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased, Haematocrit Decreased, Haemoglobin Decreased, Oedema, Transaminases Increased
Adverse event was reported on Jun 18, 2009 by a Male patient taking Posaconazole (View Usage) (Dosage: 120 Mg; Bid; Po) was diagnosed with prophylaxis, acute lymphocytic leukaemia, acute leukaemia and. Location: GERMANY , child 4 years of age, weighting 44.09 lb, After Posaconazole was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, haematocrit decreased, haemoglobin decreased, oedema, transaminases increased. During the same period patient was treated with METHOTREXATE (3900 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), VINDESINE (VINDESINE) (2.3 Mg; Qd; Iv) (View Vindesine (vindesine) Review and Vindesine (vindesine) Label ), IFOSFAMIDE (620 Mg; Bid; Iv 620 Mg; Qd; Iv) (View Ifosfamide Review and Ifosfamide Label ), GRANISETRON HCL (1 Mg; Iv) (View Granisetron Hcl Review and Granisetron Hcl Label ), DEXAMETHASONE TAB (5 Mg; Tid; Po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), COTRIM (View Cotrim Review and Cotrim Label ). Patient was hospitalized.

6251087-5 | Acute Pulmonary Oedema, Bronchopulmonary Aspergillosis, Respiratory Failure
on Jun 24, 2009 Female patient from CHINA , 29 years of age, weighting 138.9 lb, was diagnosed with fungal infection (What is fungal infection?) and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, bronchopulmonary aspergillosis, respiratory failure. Posaconazole dosage: 10 Ml; Bid; Po. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CEFOPERAZONE SODIUM (View Cefoperazone Sodium Review and Cefoperazone Sodium Label ), SULBACTAM (View Sulbactam Review and Sulbactam Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ).

6219972-8 | Acute Pulmonary Oedema, Aspergillosis, Blood Ph Decreased, Pco2 Decreased, Pulmonary Mass, Respiratory Failure
on Jun 01, 2009 Female patient from CHINA , 29 years of age, weighting 138.9 lb, was diagnosed with fungal infection (What is fungal infection?) and was treated with Posaconazole (View Usage). Patient had the following side effects: acute pulmonary oedema, aspergillosis, blood ph decreased, pco2 decreased, pulmonary mass, respiratory failure. Posaconazole dosage: 10 Ml Bid Po. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CEFOPERAZONE SODIUM (View Cefoperazone Sodium Review and Cefoperazone Sodium Label ), SULBACTAM (View Sulbactam Review and Sulbactam Label ), VANCOMYCIN HCL (View Vancomycin Hcl Review and Vancomycin Hcl Label ).

6201556-9 | Acute Myeloid Leukaemia Recurrent, Acute Respiratory Distress Syndrome, Blood Culture Positive, Dialysis, Metastases To Meninges, Multi-organ Failure, Renal Failure Acute, Septic Shock
Patient was taking Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: acute myeloid leukaemia recurrent, acute respiratory distress syndrome, blood culture positive, dialysis (What is dialysis?), metastases to meninges, multi-organ failure, renal failure acute, septic shock on May 12, 2009 from AUSTRIA Additional patient health information: Male patient , 39 years of age, weighting 191.8 lb, was diagnosed with antifungal prophylaxis, pulmonary mycosis and. Posaconazole dosage: 400 Mg; Bid; 200 Mg; Tid; 200 Mg; Qid. During the same period patient was treated with VANCOMYCIN HCL (View Vancomycin Hcl Review and Vancomycin Hcl Label ), TAZOBACTAM/PIPERACILLIN (View Tazobactam/piperacillin Review and Tazobactam/piperacillin Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ).

6189224-3 | Acute Pulmonary Oedema, Blood Ph Decreased, Pco2 Decreased, Respiratory Failure
Adverse event was reported on May 06, 2009 by a Female patient taking Posaconazole (View Usage) (Dosage: 10 Ml;bid;po) was diagnosed with fungal infection (What is fungal infection?) and. Location: CHINA , 29 years of age, weighting 138.9 lb, Patient experienced the following unwanted or unexpected effects: acute pulmonary oedema, blood ph decreased, pco2 decreased, respiratory failure. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), CEFEPERAZONE W/ SULBACTAM ) (View Cefeperazone W/ Sulbactam ) Review and Cefeperazone W/ Sulbactam ) Label ), VANCOMYCIN HCL (View Vancomycin Hcl Review and Vancomycin Hcl Label ).

6173037-2 | Blood Ph Decreased, Pulmonary Mass, Pulmonary Oedema, Rales, Refusal Of Treatment By Relative, Respiratory Failure
on Apr 23, 2009 Female patient from CHINA , 29 years of age, weighting 138.9 lb, was diagnosed with fungal infection (What is fungal infection?) and was treated with Posaconazole (View Usage). Patient had the following side effects: blood ph decreased, pulmonary mass, pulmonary oedema, rales, refusal of treatment by relative, respiratory failure. Posaconazole dosage: 10 Ml; Bid; Po.

6147047-5 | Leukaemia, Malignant Neoplasm Progression
on Mar 27, 2009 Male patient from CANADA , 70 years of age, was diagnosed with febrile neutropenia, fungal skin infection and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: leukaemia, malignant neoplasm progression. Posaconazole dosage: 400 Mg;bid;po. During the same period patient was treated with AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), LIPOSOME (View Liposome Review and Liposome Label ). Patient was hospitalized.

6122040-7 | Graft Versus Host Disease, Systemic Candida
Patient was taking Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: graft versus host disease, systemic candida on Mar 12, 2009 from FINLAND Additional patient health information: Male patient , 51 years of age, was diagnosed with antifungal prophylaxis and. Posaconazole dosage: 200 Mg; Tid. During the same period patient was treated with CASPOFUNGIN (View Caspofungin Review and Caspofungin Label ), AMBISOME (View Ambisome Review and Ambisome Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ).

6090908-6 | Eyelid Oedema, Face Oedema, Rash Pruritic
Adverse event was reported on Feb 12, 2009 by a Female patient taking Posaconazole (View Usage) (Dosage: 5 Ml; Tid; Po) was diagnosed with acute myeloid leukaemia and. Location: CHINA , 53 years of age, weighting 166.4 lb, Patient had the following side effects: eyelid oedema, face oedema, rash pruritic. During the same period patient was treated with TINIDAZOLE (TINIDAZOLE) (0.5 Gm; Qd; Po) (View Tinidazole (tinidazole) Review and Tinidazole (tinidazole) Label ), CEFTAZIDIME (2 Gm; Bid; Iv) (View Ceftazidime Review and Ceftazidime Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ).

6090246-1 | Electrocardiogram Qt Prolonged, Pneumonitis
on Feb 09, 2009 Male patient from AUSTRALIA , 70 years of age, was diagnosed with antifungal prophylaxis and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: electrocardiogram qt prolonged, pneumonitis. Posaconazole dosage: .

6088397-0 | Electrocardiogram Qt Prolonged, Pneumonitis
on Feb 09, 2009 Male patient from AUSTRALIA , 70 years of age, was diagnosed with antifungal prophylaxis and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: electrocardiogram qt prolonged, pneumonitis. Posaconazole dosage: .

6074496-6 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased, Haematocrit Decreased, Haemoglobin Decreased, Lymphocyte Percentage Decreased, Neutrophil Percentage Increased, Puncture Site Infection
Patient was taking Posaconazole (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, haematocrit decreased, haemoglobin decreased, lymphocyte percentage decreased, neutrophil percentage increased, puncture site infection on Jan 30, 2009 from GERMANY Additional patient health information: Male patient , child 4 years of age, weighting 44.09 lb, was diagnosed with prophylaxis, acute lymphocytic leukaemia and. Posaconazole dosage: 120 Mg; Bid; Po. During the same period patient was treated with METHOTREXATE (3900 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), VINDESINE (VINDESINE) (2.3 Mg; Qd; Iv) (View Vindesine (vindesine) Review and Vindesine (vindesine) Label ), IFOSFAMIDE (620 Mg; Bid; Iv, 620 Mg; Qd; Iv) (View Ifosfamide Review and Ifosfamide Label ), GRANISETRON HCL (1 Mg; Iv) (View Granisetron Hcl Review and Granisetron Hcl Label ), DEXAMETHASONE TAB (5 Mg; Tid; Po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUCONAZOL (CON.) (View Fluconazol (con.) Review and Fluconazol (con.) Label ), COTRIM (CON.) (View Cotrim (con.) Review and Cotrim (con.) Label ). Patient was hospitalized.

6068442-9 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased, Lymphoedema, Puncture Site Infection, Transaminases Increased
Adverse event was reported on Jan 26, 2009 by a Male patient taking Posaconazole (View Usage) (Dosage: 120 Mg;bid;po) was diagnosed with prophylaxis, acute lymphocytic leukaemia and. Location: GERMANY , child 4 years of age, weighting 44.09 lb, After Posaconazole was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, lymphoedema, puncture site infection, transaminases increased. During the same period patient was treated with METHOTREXATE (3900 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), VINDESINE (VINDESINE) (2.3 Mg;qd;iv) (View Vindesine (vindesine) Review and Vindesine (vindesine) Label ), IFOSFAMIDE (620 Mg;bid;iv, 620 Mg;qd;iv) (View Ifosfamide Review and Ifosfamide Label ), GRANISETRON HCL (1 Mg; ;iv) (View Granisetron Hcl Review and Granisetron Hcl Label ), DEXAMETHASONE TAB (5 Mg;tid;po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), COTRIM (View Cotrim Review and Cotrim Label ). Patient was hospitalized.

6065148-7 | Eyelid Oedema, Face Oedema, No Therapeutic Response, Rash Pruritic, Swelling Face
on Jan 22, 2009 Female patient from CHINA , 53 years of age, weighting 166.4 lb, was diagnosed with acute myeloid leukaemia, infection (What is infection?) and was treated with Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: eyelid oedema, face oedema, no therapeutic response, rash pruritic, swelling face. Posaconazole dosage: 5 Ml Tid Po. During the same period patient was treated with TINIDAZOLE (TINIDAZOLE) (0.5 Gm Qd Po) (View Tinidazole (tinidazole) Review and Tinidazole (tinidazole) Label ), CEFTAZIDIME (2 Gm Bid Iv) (View Ceftazidime Review and Ceftazidime Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ).

6058386-0 | Cerebral Infarction, Communication Disorder, Hypokalaemia, Hyponatraemia, Hypoproteinaemia, Papilloedema
on Jan 20, 2009 Male patient from GREECE , 78 years of age, was diagnosed with zygomycosis and was treated with Posaconazole (View Usage). Patient had the following side effects: cerebral infarction, communication disorder, hypokalaemia, hyponatraemia, hypoproteinaemia, papilloedema. Posaconazole dosage: . During the same period patient was treated with AMPHOTERICIN B (5 Mg/kg; Qd;) (View Amphotericin B Review and Amphotericin B Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6053152-4 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased, Puncture Site Infection
Patient was taking Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, puncture site infection on Jan 14, 2009 from GERMANY Additional patient health information: Male patient , child 4 years of age, weighting 44.09 lb, was diagnosed with acute lymphocytic leukaemia, prophylaxis and. Posaconazole dosage: 120 Mg; Bid; Po. During the same period patient was treated with METHOTREXATE (3900 Mg;qd;iv) (View Methotrexate Review and Methotrexate Label ), VINDESINE (VINDESINE) (2.3 Mg;qd;iv) (View Vindesine (vindesine) Review and Vindesine (vindesine) Label ), IFOSFAMIDE (620 Mg;bid;iv; 620 Mg;qd;iv) (View Ifosfamide Review and Ifosfamide Label ), GRANISETRON HCL (1 Mg; Iv) (View Granisetron Hcl Review and Granisetron Hcl Label ), DEXAMETHASONE TAB (5 Mg;tid;po) (View Dexamethasone Tab Review and Dexamethasone Tab Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), COTRIM (View Cotrim Review and Cotrim Label ). Patient was hospitalized.

6051907-3 | Electrocardiogram Qt Prolonged
Adverse event was reported on Jan 22, 2009 by a Female patient taking Posaconazole (View Usage) (Dosage: Posaconazole 400mg Twice Daily Po) was diagnosed with fungal infection (What is fungal infection?) and. Location: UNITED STATES , 67 years of age, weighting 95.90 lb, Patient experienced the following unwanted or unexpected effects: electrocardiogram qt prolonged.

6035325-X | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased
on Dec 25, 2008 Male patient from GERMANY , child 4 years of age, weighting 44.09 lb, was diagnosed with acute lymphocytic leukaemia, prophylaxis and was treated with Posaconazole (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased. Posaconazole dosage: 120 Mg;bid;po. During the same period patient was treated with METHOTREXATE (3900 Mg;qd;iv) (View Methotrexate Review and Methotrexate Label ), VINDESINE (2.3 Mg;qd;iv) (View Vindesine Review and Vindesine Label ), IFOSFAMIDE (620 Mg;bid;iv, 620 Mg;qd;iv) (View Ifosfamide Review and Ifosfamide Label ), GRANISETRON HCL (1 Mg; ;iv) (View Granisetron Hcl Review and Granisetron Hcl Label ), DEXAMETHASONE (5 Mg;tid;po) (View Dexamethasone Review and Dexamethasone Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), COTRIM (View Cotrim Review and Cotrim Label ). Patient was hospitalized.

5963833-6 | Central Nervous System Lesion, Coma, Convulsion, Gastrointestinal Haemorrhage, Zygomycosis
on Nov 18, 2008 Male patient from FRANCE , 55 years of age, was diagnosed with prophylaxis and was treated with Posaconazole (View Usage). After Posaconazole was administered, patient had the following side effects: central nervous system lesion, coma, convulsion, gastrointestinal haemorrhage, zygomycosis. Posaconazole dosage: 400 Mg Bid. During the same period patient was treated with STEROIDS (View Steroids Review and Steroids Label ). Patient was hospitalized.

5960870-2 | Asthenia, Convulsion, Disease Progression, Eye Pain, Facial Pain, Fungus Culture Positive, Gastrointestinal Haemorrhage, Nasal Congestion, Neurological Decompensation
Patient was taking Posaconazole (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, convulsion, disease progression, eye pain, facial pain, fungus culture positive, gastrointestinal haemorrhage, nasal congestion, neurological decompensation on Nov 11, 2008 from FRANCE Additional patient health information: Male patient , 55 years of age, was diagnosed with prophylaxis and. Posaconazole dosage: 400 Mg;bid;. During the same period patient was treated with STEROIDS (View Steroids Review and Steroids Label ). Patient was hospitalized.

5945863-3 | Metastases To Lymph Nodes, Recurrent Cancer, Skin Exfoliation, Squamous Cell Carcinoma Of Skin
Adverse event was reported on Oct 31, 2008 by a Male patient taking Posaconazole (View Usage) (Dosage: 400 Mg;bid;po) was diagnosed with systemic mycosis and. Location: UNITED KINGDOM , 50 years of age, Patient had the following side effects: metastases to lymph nodes, recurrent cancer, skin exfoliation, squamous cell carcinoma of skin. During the same period patient was treated with KEPPRA (View Keppra Review and Keppra Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ), FLUCYTOSINE (View Flucytosine Review and Flucytosine Label ).

5933674-4 |
on Oct 20, 2008 Female patient from SLOVENIA , 13 years of age, was diagnosed with systemic mycosis and was treated with Posaconazole (View Usage). . Posaconazole dosage: Po.

5929278-X |
on Oct 16, 2008 Female patient from SLOVENIA , 13 years of age, was diagnosed with systemic mycosis and was treated with Posaconazole (View Usage). . Posaconazole dosage: Po.

5928416-2 | Metastases To Lymph Nodes, Squamous Cell Carcinoma Of Skin
Patient was taking Posaconazole (View Usage). Patient had the following side effects: metastases to lymph nodes, squamous cell carcinoma of skin on Oct 13, 2008 from UNITED KINGDOM Additional patient health information: Male patient , 50 years of age, was diagnosed with fungal infection (What is fungal infection?) and. Posaconazole dosage: 400 Mg; Bid; Po. During the same period patient was treated with KEPPRA (View Keppra Review and Keppra Label ), AMPHOTERICIN B (View Amphotericin B Review and Amphotericin B Label ), CANDESARTAN CILEXETIL (View Candesartan Cilexetil Review and Candesartan Cilexetil Label ).